These findings are consistent with our previous findings highlighting how macitentan simultaneously affects tumour and stromal compartments in HG-SOC [6], and supports the idea that ET-1R blockade could be combined with other drugs, targeting the interplay between cancer cell populations within the metastatic niche. This evidence concerns the gene UBXN11 and cancer.